In situ drug synthesis catalysed by endogenous copper
Excess copper linked to Alzheimer’s disease can facilitate its own removal by catalysing the synthesis of a drug that sequesters copper, new research shows. The drug also photo-oxygenates amyloid-β plaques, causing them to break up. Tests on Alzheimer’s disease models, using the common laboratory worm Caenorhabditis elegans, showed that the therapy could suppress amyloid-β-mediated paralysis.